MDGN (NEW VIDEO!), BTE, DEI, GPI - Stock Review From DrStockPick.com!

FOR IMMEDIATE RELEASE
Chardon, Ohio, United States of America (Free-Press-Release.com) January 23, 2012 -- Medgenics, Inc. (NYSE Amex:MDGN), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced that the Company received notice of ‘Intention to Grant’ from the European Patent Office for the patent application entitled “USE OF DERMAL MICRO ORGANS,” with allowed claims covering a core element of its Biopump™ protein therapy technology.

Commenting on the European patent allowance, Andrew L. Pearlman, Ph.D., President and Chief Executive Officer ofMedgenics, said: “We will be delighted to add this European patent to our growing intellectual property portfolio. This patent is important as it protects key elements of our protein production technology. These claims provide significant protection for our proprietary technology and create significant barriers of entry to any would-be competitors.”









Read the article with full Disclaimer: http://drstockpick.com/23529/stock-alerts/mdgn-new-video-bte-dei-gpi-stock-review-from-drstockpickcom/